NCT04872387View on ClinicalTrials.gov

A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

August 4, 2021

Study Completion Date

August 26, 2021

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

BAY2586116

Nasal administration

DRUG

Placebo

Matching placebo

Trial Locations (1)

813-0017

SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04872387 - A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose | Biotech Hunter | Biotech Hunter